Johnson & Johnson (JNJ) Shares Dip After Revenue Miss, Suspended COVID Vaccine Sales Guidance; Results Seen as 'Mixed'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Johnson & Johnson (JNJ) PT Raised to $205 at Credit Suisse
April 20, 2022 6:51 AM EDTCredit Suisse analyst Matt Miksic raised the price target on Johnson & Johnson (NYSE: JNJ) to $205.00 (from $200.00) while maintaining a Outperform rating.
... MoreJohnson & Johnson (JNJ) PT Raised to $196 at Raymond James
April 20, 2022 5:56 AM EDTRaymond James analyst Jayson Bedford raised the price target on Johnson & Johnson (NYSE: JNJ) to $196.00 (from $195.00) while maintaining a Outperform rating following results.
The analyst commented, "1Q results were mixed and the downward guidance revision, although not operational, still causes us to... More
Johnson & Johnson (JNJ) PT Raised to $210 at Citi
April 19, 2022 3:11 PM EDTCiti analyst Joanna Wuensch raised the price target on Johnson & Johnson (NYSE: JNJ) to $210.00 (from $203.00) while maintaining a Buy rating following earnings.
... More